High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas

Blood

Volumn 119, Issue 6, 2012, Pages 1479-1489

  Zocchi, Maria Raffaella ^a   Catellani, Silvia ^a   Canevali, Paolo ^a   Tavella, Sara ^b   Garuti, Anna ^b   Villaggio, Barbara ^b   Zunino, Annalisa ^b   Gobbi, Marco ^b   Fraternali Orcioni, Giulio ^b   Kunkl, Annalisa ^b   Ravetti, Jean Louis ^b   Boero, Silvia ^b   Musso, Alessandra ^b   Poggi, Alessandro ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSFORMING GROWTH FACTOR BETA; UL16 BINDING PROTEIN 3; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; AGED; ARTICLE; BETA RHYTHM; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CYTOTOXICITY; DOWN REGULATION; FEMALE; GAMMA DELTA T LYMPHOCYTE; HODGKIN DISEASE; HUMAN; LYMPH NODE; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; T LYMPHOCYTE; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

EID: 84856836302     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-370841     Document Type: Article

References (48)

1. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3(10):781-790. (Pubitemid 37328656)
2. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity. 2009;31(2):184-196.
3. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene. 2008;27(45):5944-5958.
4. González S, López-Soto A, Suarez-Alvarez B, López-Vázquez A, López-Larrea C. NKG2D ligands: key targets of the immune response. Trends Immunol. 2008;29(8):397-403.
5. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010;235(1):267-285.
6. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by gamma delta T cells. Science. 2001;294(5542):605-609. (Pubitemid 32999559)
7. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A. 1999;96(12):6879-6884. (Pubitemid 29274978)
8. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rael and HL60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413(6852):165-171. (Pubitemid 32867877)
9. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class-I-related molecules, bind to CMV glicoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123-133. (Pubitemid 32206515)
10. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobiphosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood. 2000;96(2):384-392. (Pubitemid 30463353)
11. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol. 2002;23(1):14-17.
12. Street SE, Hayakawa Y, Zhan Y, et al. Innate immune surveillance of spontaneous B cell lymphoma by natural killer and gammadelta T cells. J Exp Med. 2004;199(6):879-884. (Pubitemid 38375207)
13. Wilhelm M, Kunzman V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients. Blood. 2003;102(1):200-206.
14. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389-1396. (Pubitemid 36988048)
15. Poggi A, Venturino C, Catellani S, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and upregulated by trans-retinoic acid. Cancer Res. 2004;64(24):9172-9179. (Pubitemid 39665533)
16. Catellani S, Poggi A, Bruzzone A, et al. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood. 2007;109(5):2078-2085. (Pubitemid 46348208)
17. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T lymphocytes in tumor immunology. Cancer Res. 2007;67(1):5-8. (Pubitemid 46142752)
18. Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature. 2002;419(6908):734-738. (Pubitemid 35177960)
19. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 2006;66(5):2520-2526.
20. Kaiser BK, Yim D, Chow I-T, et al. Disulphide-isomerase-enabled shedding of tumor-associated NKG2D ligands. Nature. 2007;447(7143):482-487.
21. Jinushi M, Vanneman M, Munshi NC, et al. MIC-A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008;105:1285-1290. (Pubitemid 351397045)
22. Waldhauer I, Goehlsdorf D, Gieseke F, et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008;68(15):6368-6376.
23. Fernández-Messina L, Ashiiru O, Boutet P, et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem. 2010;285(12):8543-8551.
24. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172(12):7335-7340. (Pubitemid 38747593)
25. Kopp H-G, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer antitumor reactivity. Cancer Res. 2009;69(19):7775-7783.
26. Ghio M, Contini P, Negrini S, Boero S, Musso A, Poggi A. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur J Immunol. 2009;39(12):3459-3468.
27. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-transretinoic acid or sodium valproate. Leukemia. 2009;23(4):641-648.
28. Nückel H, Switala M, Sellmann L, et al. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia. 2010;24(6):1152-1159.
29. Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010;116(20):e90-e98.
30. Musso A, Zocchi MR, Poggi A. Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival. Haematologica. 2011;96(1):16-23.
31. Poggi A, Zancolli M, Boero S, Catellani S, Musso A, Zocchi MR. Differential survival of gammadeltaT cells, alphabetaT cells and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells. Int J Cancer. 2011;129(2):387-396.
32. Sonne SB, Dalgaard MD, Nielsen JE, et al. Optimizing staining protocols for Laser Microdissection of specific cell types from the testis including carcinoma in situ. PLoS One. 2009;4(5):e5536.
33. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357. (Pubitemid 38072573)
34. Fleige S, Walf V, Huch S, Prgomet C, Sehm J, Pfaffl MW. Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett. 2006;28(19):1601-1613. (Pubitemid 44306128)
35. Kong Y, Cao W, Xi X, Ma C, Cui L, He W. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood. 2009;114(2):310-317.
36. Lança T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood. 2010;115(12):2407-2411.
37. Carbone A, Gloghini A, Cabras A, Elia G. The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol. 2009;145(4):468-480.
38. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65(14):6321-6329. (Pubitemid 40994418)
39. Diermayr S, Himmelreich H, Durovic B, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood. 2008;111(3):1428-1436. (Pubitemid 351213430)
40. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103(5):1755-1762. (Pubitemid 38268969)
41. Herbst H, Foss HD, Samol J, et al. Frequent expression of interleukin-10 by Epstein-Barr virus harbouring tumor cells of Hodgkin's disease. Blood. 1996;87(7):2918-2929. (Pubitemid 26102243)
42. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99(12):4283-4297. (Pubitemid 34627193)
43. Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT. Proteasome regulation of ULBP1 transcription. J Immunol. 2009;182(10):6600-6609.
44. von Strandmann E, Hansen HP, Reiners KS, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2006;107(5):1955-1962. (Pubitemid 43289377)
45. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 2004;64(20):7596-7603. (Pubitemid 39372105)
46. Kohga K, Takehara T, Tatsumi T, et al. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res. 2009;69(20):8050-8057.
47. Wu JD, Atteridge CL,Wang X, Seya T, Plymate SR. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res. 2009;15(2):632-640.
48. Wang X, Lundgren AD, Singh P, Goodlett DR, Plymate SR, Wu JD. A six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding. Biochem Biophys Res Commun. 2009;387(3):476-481.